Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.
dc.contributor.author | Ramírez Carracedo, Rafael | |
dc.contributor.author | Tesoro Santos, Laura | |
dc.contributor.author | Hernández, Ignacio | |
dc.contributor.author | Díez Mata, Javier | |
dc.contributor.author | Piñeiro, David | |
dc.contributor.author | Hernández Jiménez, Macarena | |
dc.contributor.author | Zamorano, José Luis | |
dc.contributor.author | Zaragoza Sánchez, Carlos | |
dc.date.accessioned | 2020-09-11T09:34:09Z | |
dc.date.available | 2020-09-11T09:34:09Z | |
dc.date.issued | 2020 | |
dc.description.abstract | Toll-like receptor 4 (TLR4) contributes to the pathogenesis of coronary ischemia/reperfusion (IR). To test whether the new TLR4 antagonist, ApTOLL, may prevent coronary IR damage, we administered 0.078 mg/kg ApTOLL or Placebo in pigs subjected to IR, analyzing the levels of cardiac troponins, matrix metalloproteinases, pro-, and anti-inflammatory cytokines, heart function, and tissue integrity over a period of 7 days after IR. Our results show that ApTOLL reduced cardiac troponin-1 24 h after administration, improving heart function, as detected by a significant recovery of the left ventricle ejection fraction (LVEF) and the shortening fraction (FS) cardiac parameters. The extension of necrotic and fibrotic areas was also reduced, as detected by Evans blue/2,3,5-triphenyltetrazolium chloride (TTC) staining, Hematoxylin/Eosine, and Masson Trichrome staining of heart sections, together with a significant reduction in the expression of the extracellular matrix-degrading, matrix metalloproteinase 9. Finally, the expression of the following cytokines, CCL1, CCL2, MIP1-A-B, CCL5, CD40L, C5/C5A, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INF-g, IL1-a, ILI-b, IL-1Ra, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17- E, IL18, IL21, IL27, IL32, MIF, SERPIN-E1, TNF-a, and TREM-1, were also assayed, detecting a pronounced decrease of pro-inflammatory cytokines after 7 days of treatment with ApTOLL. Altogether, our results show that ApTOLL is a promising new tool for the treatment of acute myocardial infarction (AMI). | spa |
dc.description.extent | 3782 KB | spa |
dc.identifier.doi | 10.3390/biom10081167 | spa |
dc.identifier.issn | 2218-273X | spa |
dc.identifier.uri | http://hdl.handle.net/10641/1964 | |
dc.language.iso | eng | spa |
dc.publisher | Biomolecules | spa |
dc.relation.publisherversion | https://www.mdpi.com/2218-273X/10/8/1167 | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.accessRights | open access | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Toll-like receptor 4 | spa |
dc.subject | Acutemyocardial infarction | spa |
dc.subject | Cytokines | spa |
dc.subject | Matrixmetalloproteinases | spa |
dc.title | Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | a1854c1f-1c01-4cee-a866-fd372311dc18 | |
relation.isAuthorOfPublication | f739a89c-f1cb-4d99-a0e8-560a8b063182 | |
relation.isAuthorOfPublication | d8b48195-2b61-490d-8a8f-69b4079a6847 | |
relation.isAuthorOfPublication.latestForDiscovery | a1854c1f-1c01-4cee-a866-fd372311dc18 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 1.- Targeting TLR4 with ApTOLL.pdf
- Size:
- 3.69 MB
- Format:
- Adobe Portable Document Format
- Description: